Telesis Bio Stock Performance
| TBIO Stock | USD 0.06 0 7.84% |
Telesis Bio holds a performance score of 17 on a scale of zero to a hundred. The entity has a beta of 24.08, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Telesis Bio will likely underperform. Use Telesis Bio jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Telesis Bio.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Telesis Bio are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal forward indicators, Telesis Bio displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Telesis |
Telesis Bio Relative Risk vs. Return Landscape
If you would invest 1.20 in Telesis Bio on November 1, 2025 and sell it today you would earn a total of 4.30 from holding Telesis Bio or generate 358.33% return on investment over 90 days. Telesis Bio is currently generating 29.2561% in daily expected returns and assumes 135.6638% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Telesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Telesis Bio Target Price Odds to finish over Current Price
The tendency of Telesis Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.06 | 90 days | 0.06 | about 17.69 |
Based on a normal probability distribution, the odds of Telesis Bio to move above the current price in 90 days from now is about 17.69 (This Telesis Bio probability density function shows the probability of Telesis Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 24.08 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Telesis Bio will likely underperform. In addition to that Telesis Bio has an alpha of 25.3509, implying that it can generate a 25.35 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Telesis Bio Price Density |
| Price |
Predictive Modules for Telesis Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Telesis Bio. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Telesis Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Telesis Bio is not an exception. The market had few large corrections towards the Telesis Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Telesis Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Telesis Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 25.35 | |
β | Beta against Dow Jones | 24.08 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | 0.20 |
Telesis Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Telesis Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Telesis Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Telesis Bio is way too risky over 90 days horizon | |
| Telesis Bio has some characteristics of a very speculative penny stock | |
| Telesis Bio appears to be risky and price may revert if volatility continues | |
| Telesis Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 27.51 M. Net Loss for the year was (47.72 M) with profit before overhead, payroll, taxes, and interest of 15.6 M. | |
| Telesis Bio currently holds about 654.75 M in cash with (34.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
Telesis Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Telesis Pink Sheet often depends not only on the future outlook of the current and potential Telesis Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Telesis Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.8 M | |
| Cash And Short Term Investments | 19.3 M |
Telesis Bio Fundamentals Growth
Telesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Telesis Bio, and Telesis Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telesis Pink Sheet performance.
| Return On Equity | -1.48 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.53) % | |||
| Operating Margin | (6.76) % | |||
| Current Valuation | 61.1 M | |||
| Shares Outstanding | 1.77 M | |||
| Price To Earning | 71.32 X | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 27.51 M | |||
| EBITDA | (31.05 M) | |||
| Cash And Equivalents | 654.75 M | |||
| Cash Per Share | 8.70 X | |||
| Total Debt | 34.38 M | |||
| Debt To Equity | 0.16 % | |||
| Book Value Per Share | (11.59) X | |||
| Cash Flow From Operations | (34.67 M) | |||
| Earnings Per Share | (30.42) X | |||
| Total Asset | 70.41 M | |||
| Retained Earnings | (161.47 M) | |||
| Current Asset | 3.28 M | |||
| Current Liabilities | 16.98 M | |||
About Telesis Bio Performance
By examining Telesis Bio's fundamental ratios, stakeholders can obtain critical insights into Telesis Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Telesis Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.Things to note about Telesis Bio performance evaluation
Checking the ongoing alerts about Telesis Bio for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Telesis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telesis Bio is way too risky over 90 days horizon | |
| Telesis Bio has some characteristics of a very speculative penny stock | |
| Telesis Bio appears to be risky and price may revert if volatility continues | |
| Telesis Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 27.51 M. Net Loss for the year was (47.72 M) with profit before overhead, payroll, taxes, and interest of 15.6 M. | |
| Telesis Bio currently holds about 654.75 M in cash with (34.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telesis Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telesis Bio's stock is overvalued or undervalued compared to its peers.
- Examining Telesis Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telesis Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telesis Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telesis Bio's pink sheet. These opinions can provide insight into Telesis Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Telesis Pink Sheet
Telesis Bio financial ratios help investors to determine whether Telesis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telesis with respect to the benefits of owning Telesis Bio security.